摘要
目的研究贝伐珠单抗联合FOLFOX方案治疗晚期结肠癌患者的临床效果。方法将2014年7月至2016年7月于本院接受治疗的148例晚期结肠癌患者作为研究对象，用数字法随机将其分成观察组（74例）和对照组（74例）。对照组接受FOLFOX治疗。观察组接受贝伐珠单抗联合FOLFOX方案治疗。治疗4周期后，利用χ2检验对比两组客观缓解率及不良反应。结果观察组总体客观缓解率优于对照组（41．89％比14．86％），差异具有统计学意义（χ2=13．297，P=O．000）。两组治疗后高血压（22．97％比36．49％）、胃肠道反应（22．97％比33．78％）以及白细胞减少（18．92％比28．38％）等不良反应发生率差异均无统计学意义（χ2=3．234、1．834、2．128，P=0．072、0．176、0．145）。结论贝伐珠单抗联合FOLFOX方案治疗晚期结肠癌患者有较好的临床效果，且安全性高，值得临床推广。
Objective To study the clinical effect of bevacizumab combined with FOLFOX regimen in the treatment of patients with advanced colorectal cancer. Methods A total of 148 patients with advanced colorectal cancer who were treated at our hospital from July, 2014 to July, 2016 were selected as study subjects and were randomly divided into an observation group （74 cases） and a control group （74 cases） with digital method. The control group were treated with FOLFOX and the observation group bevacizumab and FOLFOX. After four cycles of treatment, the clinical efficacy and adverse reactions were compared between the two groups with χ2 test. Results The objective response rate was better in the observation group than in the control group （ 41.89 % vs. 14.86 % ） , with a statistical difference （χ2=13.297, P=O.O00 ） . There were no statistical differences in the incidences of hypertension （ 22.97% vs. 36.49% ） , gastrointestinal reactions （ 22.97% vs. 33,78% ） , white blood cell decrease （ 18.92% vs. 28.38% ） , etc. between these two groups （ χ2=3.234, 1.834, 2.128; P=0.072, 0.176, 0.145 ） . Conclusions Bevacizumab combined with FOLFOX regimen in the treatment of patients with advanced colorectal cancer has a good clinical effect and high safety, so it is worth being clinically generalized.
出处
《国际医药卫生导报》
2017年第17期2754-2756,共3页
International Medicine and Health Guidance News
